Uniqure NV Form 4 insider transactions

uniQure N.V. CEO Matthew C. Kapusta executed significant stock option exercises and subsequent sales of ordinary shares totaling 296,316 shares under a pre-arranged 10b5-1 plan.

uniQure N.V.'s Chief Financial Officer, Christian Klemt, executed and sold a total of 18,000 ordinary shares in two separate transactions in late September 2025, pursuant to a pre-arranged 10b5-1 trading plan.

uniQure N.V.'s Chief Medical Officer, Walid Abi-Saab, sold 1,466 ordinary shares at a weighted average price of $13.92 to cover tax obligations related to restricted share unit vesting.

A director at uniQure N.V. sold 2,112 ordinary shares for $14.45 per share to cover estimated withholding taxes upon the vesting of restricted share units, a non-discretionary transaction.

uniQure N.V. Director Leonard E. Post sold 2,112 ordinary shares at a weighted average price of $14.45 to cover estimated withholding taxes upon the vesting of restricted share units.

A director at uniQure N.V. sold 2,112 ordinary shares for $14.45 per share to cover estimated withholding taxes upon the vesting of restricted share units.

A director at uniQure N.V. sold 2,112 ordinary shares for $14.45 per share to cover estimated withholding taxes upon the vesting of restricted share units.

Robert Gut, a Director at uniQure N.V., sold 3,336 ordinary shares at a weighted average price of $14.45 to cover estimated withholding taxes upon the vesting of restricted share units.

Madhavan Balachandran, a Director at uniQure N.V., sold 2,112 ordinary shares for $14.45 per share to cover estimated withholding taxes upon the vesting of restricted share units.

David D. Meek, a Director at uniQure N.V., sold 2,112 ordinary shares at a weighted average price of $14.45 to cover estimated withholding taxes upon the vesting of restricted share units.

Jeannette Potts, Chief Legal Officer of uniQure N.V., sold 4,670 ordinary shares at a weighted average price of $15.14 to cover estimated withholding taxes upon the vesting of restricted share units.

uniQure N.V. Director Leonard E. Post was granted 7,970 restricted share units and 15,630 stock options on June 11, 2025, as part of the company's 2014 Share Incentive Plan.

uniQure N.V. Director Jack Kaye was granted 7,970 restricted share units and 15,630 stock options as part of his compensation, aligning his interests with the company's performance.

uniQure N.V. Director Rachelle Suzanne Jacques was granted 7,970 restricted share units and 15,630 stock options on June 11, 2025, as part of the company's incentive plan.

uniQure N.V. Director Robert Gut was granted 7,970 restricted share units and stock options for 15,630 ordinary shares, as disclosed in a recent SEC Form 4 filing.

uniQure N.V. Director Madhavan Balachandran has reported the acquisition of 7,970 restricted share units and 15,630 stock options as part of his compensation.

uniQure N.V. Director Jeremy P. Springhorn was granted 7,970 restricted share units and 15,630 stock options as part of his compensation, aligning his interests with the company's long-term performance.

uniQure N.V. Director David D. Meek has reported the acquisition of 7,970 restricted share units and 15,630 stock options, granted as part of the company's 2014 Share Incentive Plan.

uniQure CEO Matthew Kapusta reports acquisition and disposal of ordinary shares and stock options.

Walid Abi-Saab, Chief Medical Officer of uniQure N.V., reports acquisition of restricted share units and stock options, as well as sales of ordinary shares to cover withholding taxes.

Christian Klemt, CFO of uniQure N.V., reports acquisition and disposal of ordinary shares, as well as a grant of stock options.

Chief Legal Officer Jeannette Potts reports acquisition of restricted share units and stock options, along with sales to cover withholding taxes.

uniQure CEO Matthew Kapusta sold shares to cover tax obligations following the vesting of restricted share units (RSUs) and performance-based restricted share units (PRSUs).

Christian Klemt, CFO of uniQure N.V., reports the sale of ordinary shares to cover withholding taxes upon the vesting of restricted share units and performance-based restricted share units.

uniQure's CEO, Matthew C. Kapusta, executed a pre-planned sale of 100,000 ordinary shares after exercising options, as part of a 10b5-1 trading plan.

uniQure CEO Matthew Kapusta acquired 10,494 ordinary shares through vested performance-based restricted share units and sold 3,418 shares to cover tax obligations.

uniQure's Chief Financial Officer, Christian Klemt, acquired shares through vested performance-based restricted share units and subsequently sold a portion to cover tax obligations.

Walid Abi-Saab, Chief Medical Officer of uniQure N.V., sold 1,447 ordinary shares to cover withholding taxes upon the vesting of restricted share units.

Director Robert Gut receives stock options and restricted share units from uniQure N.V.

Director Jeremy P. Springhorn acquired shares and options in uniQure N.V. on June 19, 2024, according to a Form 4 filing.